Skip to content

A Study to Characterize Puff Topography With Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers

A Study to Characterize Puff Topography With Use of a JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03596034
Enrollment
30
Registered
2018-07-23
Start date
2018-08-09
Completion date
2018-09-26
Last updated
2021-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nicotine Dependence, Other Tobacco Product, Tobacco Smoking, Tobacco Use

Keywords

Electronic Nicotine Delivery System (ENDS), ENDS, Puff Topography

Brief summary

A Study to Characterize Puff Topography with Use of a JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers

Detailed description

This will be an open label study to evaluate puff topography in adult smokers using a JUUL 5% ENDS. Up to 30 subjects will be enrolled and evaluated on Day 1 and Day 15. The duration of the study is 15 days with up to a 28 days screening window.

Interventions

OTHERJUUL 5%, Virginia Tobacco, ENDS product

Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.

Sponsors

Rose Research Center, LLC
CollaboratorINDUSTRY
Juul Labs, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Key Inclusion Criteria: 1. Healthy, adult, male or female smoker, 21 to 65 years of age 2. Has been a smoker for at least 12 months prior to Screening. 3. Currently smokes an average of 5 to 40 manufactured combustible (menthol or non menthol) cigarettes per day. 4. A female subject of childbearing potential must have been using 1 of the following forms of contraception and agree to continue using it through completion of the study 5. Provides voluntary consent to participate in this study documented on the signed informed consent form. Key

Exclusion criteria

1. Has a clinically significant abnormal finding on the physical examination, medical history, vital signs, ECG, or clinical laboratory results, in the opinion of the PI. 2. Has a body mass index (BMI) \> 40 kg/m2 or \< 18 kg/m2 at Screening. 3. Has a history of drug or alcohol abuse within 24 months of Day 1. 4. If female, the subject is pregnant, lactating, or intends to become pregnant during the time period from Screening through the end of study.

Design outcomes

Primary

MeasureTime frameDescription
Puff Topography Parameter - Puff Duration15 daysTo characterize overall puff duration
Puff Topography Parameter - Puff Volume15 daysTo characterize overall puff volume
Puff Topography Parameter - Peak Puff Flow Rate15 daysTo characterize overall peak puff flow rate
Puff Topography Parameter - Average Puff Flow Rate15 daysTo characterize overall average puff flow
Puff Topography Parameter - Inter-Puff Interval15 daysTo characterize overall inter-puff interval (time between puffs)

Secondary

MeasureTime frameDescription
Subject measure of affect15 daysAssessment of affect using the Positive and Negative Affect Scale (PANAS). Scale consists of a number of words that describe different feelings and emotions. Scale 1 (Very Slightly or Not at All), 2 (A Little), 3 (Moderately), 4 (Quite a Bit), 5 (Extremely).
Self-reported product use over 15-day period15 daysTo assess the relationship between puff topography parameters and self-reported product use (number of puffs per day and number of JUULpods started each day) in a 15-day product use period.
Subjective measure of nicotine withdrawal15 daysAssessment of nicotine withdrawal using the Nicotine Withdrawal Scale (MNWS-R). Scale consists of 15 words/statements that describe different feelings. Scale 0 (None) to 4 (Severe).
Subjective measure of product liking15 daysTo assess the relationship between puff topography parameters and JUUL 5% ENDs liking using a Product Liking Questionnaire. Visual analogue scale with scale 0 (Not at all) to 100 (Extremely) in response to question I like using the JUUL Product.
Subjective measure of cigarette dependence15 daysAssessment of cigarette dependence with Fagerstrom Test for Cigarette Dependence Questionnaire (FTCD). Questionnaire consists of 6 questions.
Subjective measure of smoking urges15 daysAssessment of current smoking urge with Questionnaire of Smoking Urges - Brief (QAU-B). Responses to various statements with scale 1 (Strongly Disagree) to 7 (Strongly Agree).
Subjective measure of effects of nicotine15 daysAssessment of nicotine using the Direct Effects of Nicotine Scale. Visual analogue scale with scale 0 (Not at All) to 100 (Extremely) in response to words describing how the subject feels.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026